EUVIMEDEUVIMED entdecken
Crossref

Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial

Deborah B Doroshow iD, Geoffrey I Shapiro, Khanh Do, Vicki L Keedy, Haider Mahdi, Davendra P S Sohal, Navid Hafez, Patricia M LoRusso, Michael Cecchini iD, Jeffrey Sklar, Peter Mortimer, Colin Glover und 3 weitere

Cancer · 15.03.2026 · 132 (6)

DOI: 10.1002/cncr.70332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 11.03.2026. Verfasst von Deborah B Doroshow und 14 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cancer Center, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Antineoplastic Combined Chemotherapy Protocols, Recombinational DNA Repair. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mutations in genes encoding proteins involved the DNA damage response (DDR) occur in up to 20% of patients with cancer. It is unknown whether poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, alone or in combination with ATR or AKT inhibitors, have histology‐agnostic clinical efficacy in tumors with DDR mutations or PI3K/AKT pathway mutations, respectively.

Methods

The Olaparib Combinations (OLAPCO) trial enrolled patients in treatment arms based on next‐generation sequencing results. In cohorts 1 and 2, patients with tumors harboring DDR mutations received either the PARP inhibitor olaparib or olaparib and the ATR inhibitor ceralasertib. In cohort 3, patients with tumors with PI3K‐AKT pathway alterations or ARID1A mutations received olaparib and capivasertib. The primary end point was overall response rate (ORR) at 16 weeks assessed by the Response Evaluation Criteria in Solid Tumors, version 1.1.

Results

Sixty‐six patients were treated, including 26 on olaparib monotherapy, 24 on olaparib and ceralasertib, and 16 on olaparib and capivasertib. Among all patients treated, the ORR was 6.1% and the clinical benefit rate was 31.2% with a median duration of benefit (DoB) of 11 months. Among seven patients with platinum‐ and PARP inhibitor‐resistant high‐grade ovarian serous cancer in the olaparib and ceralasertib arm, one had a partial response and four had stable disease with a median DoB of 10 months. No unexpected toxicities were observed.

Conclusion

The study failed to meet its primary end point of ORR. DDR and homologous recombination repair defects are not consistently actionable with olaparib as monotherapy or in combination with other targeted therapies in a histology‐agnostic manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesPhthalazinesAntineoplastic Combined Chemotherapy ProtocolsRecombinational DNA RepairDNA DamageNeoplasmsHumansFemaleMiddle AgedPoly(ADP-ribose) Polymerase InhibitorsAgedAdultPyrimidinesMaleMutationAged, 80 and overProto-Oncogene Proteins c-aktMorpholinesIndolesPyrrolesSulfonamides

Stichwörter der Autor:innen

AKTATRDNA damage responsePARPhomologous recombination repairolaparibovarian carcinoma

Substanzen

olaparibPiperazinesPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsPyrimidinesceralasertibcapivasertibProto-Oncogene Proteins c-aktMorpholinesIndoles

Autor:innen und Institutionen

  • Yale Cancer Center, New Haven, Connecticut, USA.
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Cleveland Clinic, Cleveland, Ohio, USA.
  • AstraZeneca, Cambridge, Massachusetts, USA.

ORCID-Profile: Deborah B Doroshow, Michael Cecchini

Förderung

  • AstraZeneca

Zitieren

APA

Doroshow, D. B., Shapiro, G. I., Do, K., Keedy, V. L., Mahdi, H., Sohal, D. P. S., Hafez, N., LoRusso, P. M., Cecchini, M., Sklar, J., Mortimer, P., Glover, C., Moses, J., Jürgensmeier, J. M., & Eder, J. P. (2026). Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial. Cancer, 132(6). https://doi.org/10.1002/cncr.70332

Vancouver

Doroshow DB, Shapiro GI, Do K, Keedy VL, Mahdi H, Sohal DPS, et al. Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial. Cancer. 2026;132(6). doi:10.1002/cncr.70332

BibTeX
@article{Doroshow2026,
  author = {Doroshow, Deborah B and Shapiro, Geoffrey I and Do, Khanh and Keedy, Vicki L and Mahdi, Haider and Sohal, Davendra P S and Hafez, Navid and LoRusso, Patricia M and Cecchini, Michael and Sklar, Jeffrey and Mortimer, Peter and Glover, Colin and Moses, Jacqueline and Jürgensmeier, Juliane M and Eder, Joseph P},
  title = {Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {6},
  doi = {10.1002/cncr.70332}
}
Kostenlos starten →